The DOI matches its Crossref record; 244 of the 244 references it cites were found in a registry or an index; 118 of the 220 sources its claims cite were checked for support.
Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages
Open accessAbstract
Chronic liver diseases represent a major global health burden, with fibrosis as the common pathological outcome of sustained hepatic injury. Once considered irreversible, liver fibrosis is now recognized as a dynamic and potentially reversible process driven by complex cellular and molecular interactions within the hepatic microenvironment. Among these, hepatic macrophages have emerged as central regulators of both fibrogenesis and fibrosis resolution due to their remarkable phenotypic and functional plasticity. This review integrate experimental, translational, and emerging clinical evidence to propose macrophage reprogramming as a unifying therapeutic framework for liver fibrosis. A broad spectrum of intervention strategies -including gene modulation, pharmacological agents, immunometabolic reprogramming, nanotechnology-based delivery systems, and cell-based therapies- converges on promoting restorative macrophage phenotypes across toxic, metabolic, cholestatic, and inflammatory liver diseases. Particular emphasis is placed on key signaling and metabolic circuits -such as NF-κB, STAT1/3/6, PPARα/γ, AMPK, mitochondrial function, and autophagy- that collectively govern macrophage fate and function. The context-dependent nature of macrophage responses is highlighted, underscoring critical differences between toxic injury models (e.g., CCl 4 ) and chronic metabolic conditions such as MASH, where macrophage heterogeneity and immunometabolic dysregulation impose additional therapeutic challenges. Emerging clinical data indicate that many antifibrotic strategies -despite distinct primary targets- converge on shared pathways of macrophage modulation, reinforcing their role as integrative hubs linking inflammation, metabolism, and tissue repair. Collectively, current findings indicate that durable fibrosis regression is unlikely to be achieved through single-target interventions. Instead, effective therapeutic strategies will require coordinated, temporally defined modulation of macrophages alongside other hepatic cells populations. Elucidation of the hierarchy and timing of macrophage-driven repair processes will be essential for the rational design of next-generation antifibrotic interventions with improved clinical efficacy.
Overview
CoChat Summary
TL;DR
This review argues that liver fibrosis is potentially reversible and that restorative macrophages are central to fibrosis resolution through coordinated immunometabolic reprogramming, efferocytosis, and matrix remodeling. It surveys experimental and clinical evidence showing that many antifibrotic strategies converge on macrophage modulation, with the strongest translational support currently for metabolic therapies such as SGLT2 inhibitors and GLP-1 receptor agonists.
Key findings
- Restorative macrophages are described as promoting fibrosis resolution by enhancing extracellular matrix degradation, inactivating or eliminating activated HSCs, and supporting tissue repair; they secrete IGF-I and HGF and are linked to increased MMP activity and reduced collagen deposition.
- In mouse models, fibrosis regression is associated with macrophage phenotypes shaped by signaling and metabolic pathways including NF-κB, STATs, PPARs, AMPK, mitochondrial function, and autophagy; for example, TRPM2 activation increases phagocytosis and promotes a restorative phenotype, and SGLT2 inhibition shifts macrophage metabolism from glycolysis to oxidative phosphorylation.
- Clinical evidence summarized in the review includes a randomized trial of pioglitazone in 55 patients, where fibrosis reduction was not statistically significant after 6 months, and later trials of metabolic therapies such as tirzepatide and semaglutide showing fibrosis benefit; semaglutide achieved at least a one-stage fibrosis improvement without worsening steatohepatitis in 36.8% vs 22.4% with placebo at week 72.
- The review states that in a 104-week trial with 695 adults with T2DM on metformin, combined exenatide plus dapagliflozin produced greater improvements in hepatic steatosis and fibrosis markers than either agent alone.
Methods
- Narrative review integrating experimental, translational, and clinical evidence on macrophage reprogramming in liver fibrosis across toxic, metabolic, cholestatic, and inflammatory liver diseases.
- The paper synthesizes studies using murine models (including CCl4, MASH/MASLD, BDL, alcoholic liver disease, and others), human liver tissue/single-cell studies, and clinical trials; it also refers to summary Tables 1–7.
- Main analysis is thematic: it organizes findings by macrophage heterogeneity, mechanistic pathways, therapeutic strategies, risks/context dependence, and translational/clinical evidence.
Limitations
- The paper explicitly notes that most mechanistic studies rely on in vitro work, frequently using RAW264.7 cells, which “do not faithfully recapitulate” liver macrophages and should be interpreted with caution; this is a stated limitation.
- It also states that many antifibrotic studies did not systematically assess temporal dynamics or compare effects across distinct hepatic cell populations, limiting mechanistic clarity; this is a stated limitation.
- Evident from the text: much of the evidence is preclinical and murine, with several clinical interventions showing variable efficacy or limited durability, so direct clinical translation remains uncertain.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
84 Valid · 5 Not valid · 69 Not checked · 45 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“CCAAT/enhancer-binding protein α (C/EBPα) promotes restorative polarization in murine macrophages (75, 78).”
§ Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages > Mechanistic basis of restorative macrophages > Other pathways in the transcriptional regulation of restorative macrophages
What the sources say
- Not checked — no full text of the sourcecites [75] Jansakun, 2023, Myeloid- and hepatocyte-specific deletion of group VIA calcium-independent phospholipase A2 leads to dichotomous opposing phenotypes during MCD diet-induced NASH, Biochim Biophys Acta Mol Basis Dis source
- Disputedcites [78] Saijou, 2018, Neutrophils alleviate fibrosis in the CCl(4)-induced mouse chronic liver injury model, Hepatol Commun sourceExperimental — accuracy not yet measured
The paper’s background passage (indexed under Abstract; page unavailable) says C/EBPα rises during granulocytic differentiation but falls during the alternative monocytic pathway. It also reports that Trib1 loss, associated with increased C/EBPα, reduced M2-like macrophages; the Discussion instead links C/EBPα to increased neutrophil production. These passages point away from the claimed promotion of restorative macrophage polarization. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“As shown by Weng et al. (65), IL-4Rα deficiency -despite its role in monocyte-to-resolutive macrophage differentiation- can paradoxically exacerbate fibrosis when present during active fibrogenesis, emphasizing the stage- and context-dependent nature of macrophage reprogramming.”
§ Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages > Strategies inducing restorative macrophages in liver fibrosis > NAFLD/NASH (MASLD/MASH) models
What the sources say
- Disputedcites [65] Weng, 2018, IL-4 receptor alpha signaling through macrophages differentially regulates liver fibrosis progression and reversal, EBioMedicine sourceExperimental — accuracy not yet measured
The Results section (“IL-4Rα Deficiency Retards Progression of Liver Fibrosis”; page unavailable) reports that IL-4Rα-deficient mice developed significantly less fibrosis during active CCl4-induced progression, not more. The Discussion does mention increased fibrosis in IL-4Rα-deficient mice with chronic schistosomiasis, but identifies that as a finding from Vannella et al. (2014), a different disease context. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“Notably, during disease regression, fibrosis resolution was associated not with the emergence of new macrophage subsets but with a shift in population dynamics.”
§ Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages > Liver macrophage heterogeneity and plasticity in fibrosis
What the sources say
- Supportedcites [10] Ganguly, 2024, Lipid-associated macrophages' promotion of fibrosis resolution during MASH regression requires TREM2, Proc Natl Acad Sci USA source
The Results section reports that during MASH regression, no new transcriptionally distinct macrophage subpopulation emerged, but the relative composition of macrophage clusters changed. The Discussion likewise states that no new subpopulation emerged and that population dynamics changed. The finding concerns MASH regression in the studied mouse models; page numbers were not provided. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“They secrete growth factors such as insulin-like growth factor-I (IGF-I) and hepatocyte growth factor (HGF), which support tissue repair and regeneration (1–4).”
§ Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages > Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Ramachandran, 2012, Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis, Proc Natl Acad Sci USA source
- Partly supportedcites [2] Borda, 2024, The antifibrotic potential of IMT504: modulation of GLAST + Wnt1 + bone marrow stromal progenitors and hepatic microenvironment, Stem Cell Res Ther sourceExperimental — accuracy not yet measured
The Results section reports that treated fibrotic-liver macrophages acquired a proregenerative phenotype marked by increased HGF expression. It reports increased HGF and IGF-I mRNA in hepatocytes, not macrophages, and does not establish that restorative macrophages secrete both growth factors. (LLM, conf=0.87)
- Partly supportedcites [3] Watanabe, 2019, Mesenchymal stem cells and induced bone marrow-derived macrophages synergistically improve liver fibrosis in mice, Stem Cells Transl Med sourceExperimental — accuracy not yet measured
The Introduction describes macrophage-derived proregenerative factors, and the Results report increased HGF mRNA in liver tissue after combined cell therapy (page numbers unavailable). These passages support a role in liver regeneration, but they do not identify macrophages as the source of HGF or show that they secrete it; the copy also does not report macrophage secretion of IGF-I. (LLM, conf=0.86)
- Partly supportedcites [4] Moreno-Lanceta, 2023, RNF41 orchestrates macrophage-driven fibrosis resolution and hepatic regeneration, Sci Transl Med sourceExperimental — accuracy not yet measured
The Results section reports that conditioned medium from RNF41-treated macrophages stimulated hepatocyte proliferation and that blocking IGF-1 reduced this effect. It does not support the HGF part: HGF was not affected in the treated mice, and the Discussion says IGF-1 rather than HGF participated in the proregenerative effect. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Transcriptomic analyses further revealed that NF-κB–dependent inflammatory genes are major downstream targets of the histone methyltransferase MLL4 (14), which directly interacts with the NF-κB subunit p65 and is required for its full transcriptional activity.”
§ Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages > Mechanistic basis of restorative macrophages
What the sources say
- Supportedcites [14] Lee, 2024, The methyltransferase MLL4 promotes nonalcoholic steatohepatitis by enhancing NF-kappaB signaling, J Biol Chem source
The Results section on MCDD-dependent transcriptome changes reports that inflammatory-response genes were significantly affected by reduced MLL4 expression. The section on NF-κB as a key mediator identifies NF-κB signaling among the downregulated pathways and reports that MLL4 interacts with p65 and supports its transcriptional activity. Page numbers are not available in our copy. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
105 more claims · 34 with their cited sources checked
Create a free account to see all 203 claims and to verify the 16 references still open.
- It may state two separate claims as one. 89
- Borderline: one of the tests for a substantial claim is unclear. 2
- Probably not a substantial claim. 3
- The quote only partly states this claim. 3
Citations
Cites
Identification of splenic reservoir monocytes and their deployment to inflammatory sites
Swirski, F. K., Nahrendorf, M., Etzrodt, M., Wildgruber, M., Cortez-Retamozo, V., Panizzi, P., Figueiredo, J.-L., Kohler, R. H., Chudnovskiy, A., Waterman, P., et al. (2009) · Science · doi:10.1126/science.1175202 · Cited by 2,221
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Resolving the fibrotic niche of human liver cirrhosis at single-cell level
Ramachandran, P., Dobie, R., Wilson-Kanamori, J. R., Dora, E. F., Henderson, B. E. P., Luu, N. T., Portman, J. R., Matchett, K. P., Brice, M., Marwick, J. A., et al. (2019) · Nature · doi:10.1038/s41586-019-1631-3 · Cited by 1,784
Liver Macrophages in Tissue Homeostasis and Disease
Krenkel, O., & Tacke, F. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.11 · Cited by 1,424
THP-1 cell line: An in vitro cell model for immune modulation approach
Chanput, W., Mes, J. J., & Wichers, H. J. (2014) · International Immunopharmacology · doi:10.1016/j.intimp.2014.08.002 · Cited by 1,393 · cited 1×
“Similar limitations apply to other macrophage-like cell lines, such as human THP-1, a monocytic leukemia-like cell line obtained from 1 year-old kid (239), or human histiocytic lymphoma U937 cells (240).”
Oxidative metabolism and PGC-1β attenuate macrophage-mediated inflammation
Vats, D., Mukundan, L., Odegaard, J. I., Zhang, L., Smith, K. L., Morel, C. R., Greaves, D. R., Murray, P. J., & Chawla, A. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.05.011 · Cited by 1,369
Bouhlel, M. A., Derudas, B., Rigamonti, E., Dièvart, R., Brozek, J., Haulon, S., Zawadzki, C., Jude, B., Torpier, G., Marx, N., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.06.010 · Cited by 1,325
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
Sanyal, A. J., Newsome, P. N., Kliers, I., Østergaard, L. H., Long, M. T., Kjær, M. S., Cali, A. M. G., Bugianesi, E., Rinella, M. E., Roden, M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2413258 · Cited by 1,115
Rodríguez-Prados, J.-C., Través, P. G., Cuenca, J., Rico, D., Aragonés, J., Martín-Sanz, P., Cascante, M., & Boscá, L. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901698 · Cited by 1,022
Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis
Loomba, R., Hartman, M. L., Lawitz, E. J., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Behling, C., Cummings, O. W., Tang, Y., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401943 · Cited by 1,005
Cited by
Li, Z., Kwan, X., Liu, Q., Chong, J., Jiang, X., Wang, J., 陈少东, & Liang, H. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48100988
Metadata
- Authors
- Aquino, J. B.
- Affiliations
- Consejo Nacional de Investigaciones Científicas y Técnicas (AR)
- Corresponding author
- Aquino, Jorge Benjamin
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2026-05-12
- Volume
- 17
- Pages
- 1792423-1792423
- ISSN
- 1664-3224 (ISSN-L)
- PMC
- PMC13201123
- OpenAlex
- W7160945889
- Semantic Scholar
- 1294f43f6d5e4d3ee79b7e800ccd4d2e6a251298
- Cited by
- 1
- References
- 243
- Citations by year
- 2026: 1
- FWCI
- 0.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Immunology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Consejo Nacional de Investigaciones Científicas y Técnicas (PIP2022)
- Agencia Nacional de Promoción Científica y Tecnológica (PICT-O-2016-0088)
- Fondo para la Investigación Científica y Tecnológica (PICT-2017-0642, PIP 2022)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- liver fibrosis, hepatic macrophages, macrophage reprogramming, fibrosis resolution, antifibrotic therapy, chronic liver disease, immunometabolic reprogramming, NF-κB signaling, PPAR signaling, AMPK, autophagy, mitochondrial function, macrophage heterogeneity, cholestatic liver disease, liver injury, cell therapy, nanotechnology drug delivery
- MeSH terms
- Metabolic Reprogramming, Animals, Humans, Liver Cirrhosis, Macrophages, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages. https://app.cochat.ai/papers/10.3389/fimmu.2026.1792423
- The paper
- Aquino, J. B. (2026). Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1792423
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.